Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Dyne Therapeutics, Inc. - Common Stock (NQ:DYN)

9.950 +0.710 (+7.68%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Dyne Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Why Thumzup Media Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
These stocks are moving in today's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks
On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ... 
Via Benzinga
Dyne Therapeutics Stock Drops After ‘Surprise’ Pivot In Primary Endpoint For Muscle Drug Trial
The updated study will enroll 60 participants and track additional measures like muscle strength, mobility, and patient-reported outcomes. 
Via Stocktwits
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Which stocks are moving on Tuesday?
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
Why Is Dyne Therapeutics Stock Trading Lower On Tuesday?
Dyne updates DYNE-101 trial timeline, reports strong 12-month data, and receives FDA Breakthrough Therapy status for treating DM1. 
Via Benzinga
Looking Into Dyne Therapeutics's Recent Short Interest
 
Via Benzinga
Peering Into Dyne Therapeutics's Recent Short Interest
 
Via Benzinga
Get insights into the top gainers and losers of Tuesday's pre-market session.
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Monday?
Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly. 
Via Investor's Business Daily
Topics Government
Booz Allen Hamilton, Movado Group And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
JPMorgan Seeks Clarity On Dyne Therapeutics' DYNE-101 Expansion, Regulatory Path
JP Morgan analysts question Dyne Therapeutics' strategy for DYNE-101 in DM1, highlighting regulatory uncertainty and investor concerns over data updates. 
Via Benzinga
Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?
Dyne Therapeutics' DYNE-101 shows promising Phase 1/2 results for myotonic dystrophy type 1, with plans for Accelerated Approval by 2026. 
Via Benzinga
Crude Oil Dips Over 4%; SPAR Group Shares Spike Higher
 
Via Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy
Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful... 
Via Benzinga
Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building
The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results. 
Via Investor's Business Daily
Nasdaq Dips Over 2%; US Construction Spending Falls In July
 
Via Benzinga
Dow Tumbles 1%; ISM Manufacturing PMI Misses Estimates
 
Via Benzinga
Topics Stocks
Boeing, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Why Low Volume In S&P 500 Could Be Signaling A Hidden Opportunity?
Find out the significance of the 
Via Talk Markets
Topics Stocks
Tech Stocks Soar, Treasury Yields Fall On Cool Inflation Data; Starbucks Rockets, Chipotle Plummets: What's Driving Markets Tuesday?
A wave of bullish sentiment swept through Wall Street on Tuesday after lower-than-expected producer inflation data solidified expectations for Federal Reserve rate cuts, prompting speculators to... 
Via Benzinga
Topics Economy
DYN Stock Earnings: Dyne Therapeutics Beats EPS for Q2 2024
DYN stock results show that Dyne Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.